



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Cilostazol for Secondary Prevention of Stroke and Cognitive Decline

Citation for published version:

Mchutchison, C, Blair, GW, Appleton, JP, Chappell, FM, Doubal, F, Bath, PM & Wardlaw, JM 2020, 'Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis', *Stroke*, vol. 51, no. 8, pp. 2374-2385. <https://doi.org/10.1161/STROKEAHA.120.029454>

Digital Object Identifier (DOI):

[10.1161/STROKEAHA.120.029454](https://doi.org/10.1161/STROKEAHA.120.029454)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Stroke

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Cilostazol for Secondary Prevention of Stroke and Cognitive Decline

Systematic Review and Meta-Analysis

Caroline McHutchison, MSc; Gordon W. Blair, MRCP; Jason P. Appleton, MCRP, PhD; Francesca M. Chappell, PhD; Fergus Doubal, PhD, FRCP; Philip M. Bath, DSc; Joanna M. Wardlaw¹, MD, FRCR, FRCP

BACKGROUND AND PURPOSE: Cilostazol, a phosphodiesterase 3' inhibitor, is used in Asia-Pacific countries for stroke prevention, but rarely used elsewhere. In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-neuron energy transfer in laboratory models, effects that may be beneficial in preventing small vessel disease progression.

METHODS: A systematic review and meta-analysis of unconfounded randomized controlled trials of cilostazol to prevent stroke, cognitive decline, or radiological small vessel disease lesion progression. Two reviewers searched for papers (January 1, 2019 to July 16, 2019) and extracted data. We calculated Peto odds ratios (ORs) and 95% CIs for recurrent ischemic, hemorrhagic stroke, death, adverse symptoms, with sensitivity analyses. The review is registered (CRD42018084742).

RESULTS: We included 20 randomized controlled trials (n=10 505), 18 in ischemic stroke (total n=10 449) and 2 in cognitive impairment (n=56); most were performed in Asia-Pacific countries. Cilostazol decreased recurrent ischemic stroke (17 trials, n=10 225, OR=0.68 [95% CI, 0.57–0.81]; $P<0.0001$), hemorrhagic stroke (16 trials, n=9736, OR=0.43 [95% CI, 0.29–0.64]; $P=0.0001$), deaths (OR=0.64 [95% CI, 0.49–0.83], $P<0.0009$), systemic bleeding (n=8387, OR=0.73 [95% CI, 0.54–0.99]; $P=0.04$), but increased headache and palpitations, compared with placebo, aspirin, or clopidogrel. Cilostazol reduced recurrent ischemic stroke more when given long (>6 months) versus short term without increasing hemorrhage, and in trials with larger proportions (>40%) of lacunar stroke. Data were insufficient to assess effects on cognition, imaging, functional outcomes, or tolerance.

CONCLUSIONS: Cilostazol appears effective for long-term secondary stroke prevention without increasing hemorrhage risk. However, most trials related to Asia-Pacific patients and more trials in Western countries should assess its effects on cognitive decline, functional outcome, and tolerance, particularly in lacunar stroke and other presentations of small vessel disease.

Key Words: aspirin ■ cilostazol ■ clopidogrel ■ meta-analysis ■ stroke, lacunar ■ stroke

Cerebral small vessel disease (SVD) causes 25% of ischemic stroke, most intracerebral hemorrhages, most vascular cognitive impairment and up to 45% of dementias, and other important aging-related comorbidities.¹ There is no specific treatment to prevent SVD progression. In a review of SVDs mechanisms and therapeutic agents with relevant modes of action,² we identified several licenced drugs including cilostazol, a

phosphodiesterase 3' inhibitor. In addition to mild antiplatelet effects,³ cilostazol has several actions targeting processes involved in SVD pathophysiology: endothelial dysfunction, myelin repair, neuroprotection, and inflammation.²

Cilostazol is used for stroke prevention in Asia-Pacific countries, but in Western countries it is used mostly for symptomatic peripheral vascular disease. Previous

Correspondence to: Joanna M. Wardlaw, Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Bldg, 49 Little France Crescent, Little France, Edinburgh, EH16 4SB, United Kingdom. Email Joanna.wardlaw@ed.ac.uk

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.120.029454>.

For Sources of Funding and Disclosures, see page 2384.

© 2020 The Authors. *Stroke* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. *Stroke* is available at www.ahajournals.org/journal/str

Nonstandard Abbreviations and Acronyms

OR	odds ratio
SVD	small vessel disease

systematic reviews suggested that cilostazol prevented recurrent stroke.^{4,5} However, further trials have been published since the last review, no review has assessed cilostazol's effects in relevant subgroups and few assessed adverse effects (bleeding, headaches, palpitations, etc) that could limit cilostazol tolerance.

We performed a systematic review and meta-analysis to determine the effect of cilostazol on stroke recurrence, cognitive decline, radiological progression of SVD, intracerebral hemorrhage, death and adverse symptoms in patients with stroke or cognitive presentations of SVD.

METHODS

We published the systematic review protocol on PROSPERO (registration No. CRD42018084742) in March 2018 and performed the review according to PRISMA standards.⁶ The data that support the findings of this study are available from the corresponding author upon request.

We searched MEDLINE and EMBASE between 1990 and July 16, 2019 (Data Supplement) for original articles reporting prospective randomized controlled trials of cilostazol in patients with stroke, SVD, mild cognitive impairment, or dementia. We also searched clinical trial registries (www.isrctn.com; <https://eudract.ema.europa.eu/>; www.strokecenter.org/), conference proceedings, bibliographies of review papers, previous systematic reviews, and trial papers for relevant trials not identified in the search, and finally for secondary publications of included trials that might provide additional outcomes.

We included randomized, controlled, unconfounded, trials in patients with stroke, mild cognitive impairment or dementia, or radiological features of SVD, who were randomized to treatment with cilostazol. Control groups received placebo tablets, another antiplatelet, or received no cilostazol (open label). We excluded trials only published as conference abstracts, where translation into English was not possible, or where the full text was not available.

We included trials that reported any of the following: recurrent stroke (all, ischemic, hemorrhagic), incident dementia, incident mild cognitive impairment, change in cognitive test scores including domain specific scores, intracranial hemorrhage, other major/fatal bleeding, other systemic bleeding complications, death, myocardial infarction, dependency in activities of daily living, symptoms related to cilostazol use (such as nausea, headache, palpitations), change in white matter hyperintensities, progression/development of lacunes, microbleeds, perivascular spaces, brain atrophy (assessed by volume or validated score).

Two reviewers screened titles and abstracts of all identified articles (G.W. Blair, C. McHutchison), independently performed full text review of relevant papers, extracted data from

included papers using standardized forms, and cross-checked their findings.

We extracted data on trial setting (hospital, community, etc), number of participants, sex, inclusion illness, diagnosis method including cognitive testing, proportion with lacunar stroke, randomization methods, time from onset of inclusion illness to randomization, blinding, treatment dose, duration, control allocation, concomitant antiplatelet or other agents, methods of outcome assessment, and proportion of patients with outcomes as listed above by intention to treat populations. We assessed study quality using the CONSORT (Consolidated Standards of Reporting Trials) criteria.⁷

Discrepancies between the 2 reviewers were resolved by discussion and a third reviewer (Dr Wardlaw) who cross-checked all data extraction.

Meta-Analysis

We entered data into RevMan5 (version 5.3) software package. For most analyses, we grouped trials according to (1) their time to randomization (randomizing in acute/subacute versus later after stroke); and (2) use of other prescribed antiplatelet drug (none, cilostazol plus aspirin or clopidogrel versus aspirin or clopidogrel, cilostazol versus aspirin or clopidogrel) and meta-analyzed each outcome. We meta-analyzed symptoms by type. For death from all causes, we assumed no deaths in studies that did not report deaths. We used Peto odds ratio (OR) and 95% CIs for the meta-analyses, a preferred method where outcome events are infrequent.⁸

In exploratory sensitivity analyses, we ranked trials according to the proportion of patients with small vessel (lacunar) ischemic stroke, dichotomized into <40% and ≥40%, or unspecified. We also tested time from stroke to start of treatment and other antiplatelet drugs used.

We performed a meta-regression to test whether time to start treatment, proportion of patients with lacunar stroke, study duration, or comparison antiplatelet agent influenced the effect of cilostazol, using R version 3.6.2 (<https://cran.r-project.org/>) meta package.

We assessed risk of bias using funnel plots and heterogeneity using I^2 and χ^2 tests.

RESULTS

We identified 572 articles but excluded 505 after abstract screening, and a further 43 after full text review (Figure 1). We included 20 unconfounded, original randomized controlled trials, published in 24 papers, including 10505 participants (Table 1).

Characteristics of Included Trials

The 20 trials had a median sample size of 183, range 20 to 2672. Eighteen trials included patients with stroke ($n=10449$, Table 1) and 2 included patients with cognitive impairment or dementia of Alzheimer's type and radiological evidence of SVD ($n=56$).^{9,10}

Of the 18 trials in patients with stroke, 2 only included patients with lacunar stroke ($n=515$),^{11,12} 3 only included patients with intracranial artery stenosis




Figure 1. PRISMA flow chart of study identification.

(n=755),^{13–15} 6 only included patients with noncardioembolic ischemic stroke (n=5264),^{16–21} most trials excluded patients with cardioembolic stroke regardless of other inclusion criteria, and one trial included patients at high risk of intracerebral hemorrhage (n=1534).²² In 9/18 trials, the stroke was lacunar in $\geq 40\%$ of participants (n=6943); in the other 9 trials, $<40\%$ of patients had a lacunar ischemic stroke or the subtype proportion was not specified (n=3262).

The time to randomization after diagnosis was <2 weeks in 8 (n=1940),^{12,14,15,19–21,23,24} between 2 weeks

and 6 months in 5 (n=2123),^{13,18,25–27} and 6 months or later in 6 trials (n=6406; including the one trial in cognitive decline/dementia)^{10,11,16,17,22,28} and was not stated in the other trial in cognitive decline.⁹ The duration of trial treatment was 4 weeks in 3 (n=344),^{19,20,28} 10 weeks in 1 (n=57),¹¹ 4 months in 4 (n=1236),^{12,20,22,23} 6 to 8 months in 5 (n=753; including both trials in cognitive decline/dementia),^{9,10,14,15,18} 12 months in 1 (n=68),²⁷ and between 12 months and 5 years in 6 trials (n=8034).^{13,16,17,22,25,26}

Eight trials used placebo tablets, the rest were open label (Table 1). One trial in stroke and one in Alzheimer's

disease tested cilostazol versus control in the absence of any other antiplatelet drug; 9 trials tested cilostazol plus aspirin or clopidogrel versus aspirin or clopidogrel; 8 trials tested cilostazol versus aspirin or clopidogrel, and 1 trial tested cilostazol plus aspirin versus clopidogrel plus aspirin.

Of the 18 trials that included patients with stroke, one²⁸ did not record recurrent stroke outcomes, and one¹⁰ that included patients with cognitive impairment reported recurrent stroke; therefore, 18 trials provided data on recurrent stroke (all, ischemic, Table I in the [Data Supplement](#)). Sixteen trials reported recurrent hemorrhagic stroke, 18 reported death, 3 trials reported cognitive outcomes (2 trials in patients with cognitive impairment, one trial in stroke),^{9–11} 10 trials reported major cardiac outcomes, 7 assessed functional outcome (modified Rankin Scale) but only 5 gave results (precluding meta-analysis of effects of cilostazol on dependency), and about half the trials reported adverse symptoms (headache, nausea, palpitations, systemic bleeding; Table II in the [Data Supplement](#)). Outcomes are summarized in Table 2.

Recurrent Ischemic Stroke

Eighteen trials (n=10225) reported recurrent ischemic stroke (cilostazol 5127, control 5098). Cilostazol decreased recurrent ischemic stroke (OR=0.68 [95% CI, 0.57–0.81]; $P<0.0001$), Figure 2, without heterogeneity. Most benefit appeared in the 9 trials testing cilostazol started >2 weeks after stroke (median 76 days; omitted in 3 trials) and given long term, where the ORs are all <1 regardless of comparator group or concomitant antiplatelet drug use (see sensitivity analyses below). In contrast, in the 8 trials starting cilostazol within 2 weeks of stroke (median 9.6 days; omitted in 4 trials) and assessing outcome at 1 to 4 months, the ORs all overlapped one, although the acute/subacute trials were smaller than the later-implementation/longer duration trials. A similar effect was seen for any recurrent stroke (18 trials, n=10225, 5127 allocated cilostazol, 5098 allocated control) where cilostazol decreased the odds of any recurrent stroke (OR=0.61 [95% CI, 0.523–0.72]; $P<0.00001$), without heterogeneity (Figure I in the [Data Supplement](#)).

Hemorrhagic Stroke

Sixteen trials (n=9736) reported recurrent hemorrhagic stroke (cilostazol 4885, control 4851). Overall, cilostazol reduced hemorrhagic stroke (OR=0.43 [95% CI, 0.29–0.64]; $P=0.0001$), Figure 3, without heterogeneity. The pattern of effect was similar to that seen in all stroke and ischemic stroke although the reduced sample resulted in fewer individually significant results.

Major Adverse Cardiovascular Events

Ten trials reported a composite outcome of major adverse cardiovascular events (cilostazol 4470, control 4478).

Cilostazol decreased major adverse cardiovascular events (OR=0.66 [95% CI, 0.57–0.76]; $P<0.00001$), without heterogeneity (Figure II in the [Data Supplement](#)). Most benefit occurred in trials testing long-term cilostazol starting 6 months or more after stroke, where summary ORs are <1 regardless of whether cilostazol was compared with placebo or aspirin or of concomitant antiplatelet drug use.

Death

Eighteen trials reported death from any cause (cilostazol 5123, control 5742). Overall, cilostazol decreased the odds of death (OR=0.64 [95% CI, 0.49–0.83]; $P=0.0009$), Figure III in the [Data Supplement](#), without heterogeneity. Most benefit occurred in trials randomizing patients late after diagnosis while trials randomizing soon after stroke were more equivocal.

Cognition

Two trials provided meta-analyzable results (cilostazol 29, control 27; Figure IV in the [Data Supplement](#)), but data were too sparse to draw conclusions. One trial (LACI-1) that could not be meta-analyzed reported a mean difference (adjusted for baseline) in Trail Making Test A of -4.0 (-12.7 to 4.7 ; $P=0.37$).

Radiological Markers of SVD

Only 3 trials reported SVD imaging markers although each reported a different measure (silent infarcts, new ischemic lesion, microbleeds). Overall 55/557 participants allocated cilostazol developed an imaging lesion compared with 48/581 allocated control (OR=1.22 [95% CI, 0.81–1.84]; $P=0.34$).

Adverse Symptoms

The types of symptoms reported by each study varied (Table II in the [Data Supplement](#)). In general, patients allocated cilostazol had more headache, dizziness, palpitations, tachycardia and diarrhea, but less constipation and nonstroke bleeding events (Table 2; Figure V in the [Data Supplement](#)). There was no heterogeneity for the above outcomes apart from systemic bleeding and palpitations (palpitations $I^2=54\%$, $\chi^2=19.43$, $P=0.02$; systemic bleeding $I^2=69\%$, $\chi^2=25.6$, $P=0.001$).

Sensitivity Analyses

Lacunar Versus Nonlacunar Stroke

In the 8 trials with <40% or unstated proportion of patients with lacunar stroke (cilostazol 1639, control 1623), cilostazol did not reduce recurrent ischemic stroke (OR=0.72 [95% CI, 0.49–1.07]; $P=0.10$, without heterogeneity), Figure VIA in the [Data Supplement](#). In the 9 trials with 40% or more patients with lacunar

Table 1. Characteristics of Included Studies

Study and Country Where Done	Study Details				
	Total n	Time From Diagnosis to Randomization	Treatment Duration	Patient Group	Stroke Subtype
ARCC ²⁸	244	At least 2 wk to ≥365 d	4 wks	Ischemic stroke	NS
Korea					
CAIST ²³	458	48 h	90 d	Ischemic stroke	58% SVD, 28% LA, 1% CE, 12% other
Korea					
CASID ⁹	36	NS	24 wk	Probable Alzheimer Disease with white matter lesions	Not applicable
Korea					
CASISP ²⁶	719	1–6 mo	Up to 540 d	Ischemic stroke	NS
China					
CATHARSIS ¹³	163	2 wks to 6 mo	2 y	Ischemic stroke, >50% stenosis ipsilateral intracranial ICA or MCA	All non-CE ischemic stroke
Japan					
CSPS ²⁵	1067	1–6 mo	Cil=632.2±467.7 d	Ischemic stroke	75% lacunar, 14% atherothrombotic 9% mixed, 2% UK
Japan			Cont=695.1±456.3 d		
CSPS2 ¹⁶	2672	Up to 26 wks	1–5 y	Non-CE ischemic stroke	65% lacunar, 32% atherothrombotic, 3% UK
Japan					
CSPS.com ¹⁷	1879	8–180 d	6 mo to 3.5 y	Non-CE ischemic stroke	49% lacunar, 42% atherothrombotic, 9% other/UK
Japan					
ECLIPse ¹²	203	7 d	90 d	Lacunar ischemic stroke	100% lacunar
Korea					
Guo et al ²⁷	68	1–6 mo	12 mo	Ischaemic stroke	NS
China					
Johkura et al ¹⁸	106	1–6 mo	6 mo	Non-CE ischemic stroke	NS but all supratentorial
Japan					c/o dizziness
LACI-1 ¹¹	57	Up to 4 y	Treatment (Cil: 9 wk; Cil+ISMN immediate start: 7 wk; Cil+ISMN delayed: 6 wk), Control: 11 wk	Lacunar stroke	100% lacunar
UK					
Lee et al ²⁴	80	Within 7 d	90 d	Ischemic stroke or TIA	NS
Korea					
Nakamura et al ¹⁹	76	48 h	6 mo	Non-CE ischemic stroke	47% SVD, 20% LA atheroma, 33% other/UK
Japan					
Ohnuki et al ²⁰	24	Within 1 wk	4 wk	Non-CE ischemic stroke	41% lacunar, 25% atherothrombotic, 6% other
Japan					
PICASSO ²²	1534	180 d	Median=1.9 y IQR=1.0–3.0	Ischemic stroke at high risk of ICH	Prior ICH or ≥2 microbleeds
Korea					
Sakurai et al ¹⁰	20	>6 mo	6 mo	Possible Alzheimer Disease and SVD lesions	Not applicable
Japan					
Shimizu (Tohoku) ²¹	507	24 h	3 mo	Non-CE progressing ischemic stroke	67% lacunar, 28% atherothrombotic, 5% other
Japan					
TOSS ¹⁴	135	2 wk	6 mo	Ischemic stroke, intracranial ICA or MCA stenosis	NS
Korea					
TOSS-2 ¹⁵	457	2 wk	7 mo	Ischemic stroke, intracranial ICA or MCA stenosis	NS
Korea					

(Continued)

Table 1. Continued

Cilostazol Group			Control Group		
Cilos-tazol n	Cilostazol Dose	Additional Treatment	Control n	Control Treatment	Control Dose
125	100 mg bd	Aspirin 100 mg daily	119	Placebo and aspirin	Aspirin 100 mg daily
231	200 mg daily	...	227	Aspirin	300 mg daily
18	100 mg bd (2 wk) then 200 mg bd	...	18	Placebo	NS
360	NS	...	359	Aspirin	NS
83	200 mg daily	Aspirin 100 mg daily	80	Aspirin	100 mg daily
533	100 mg twice daily	...	534	Placebo	100 mg twice daily
1337	100 mg twice daily	...	1335	Aspirin	81 mg daily
932	100 mg twice daily	Aspirin 81 mg or 100 mg daily or Clopidogrel 50 mg or 75 mg daily	947	Aspirin or Clopidogrel	Aspirin=81 mg or 100 mg daily Clopidogrel=50 mg or 75 mg daily
100	100 mg twice daily	Aspirin 100 mg daily	103	Placebo and aspirin	Placebo=100 mg twice daily Aspirin=100 mg daily
34	100 mg twice daily	...	34	Aspirin	100 mg daily
57	200 mg daily	...	49	Aspirin	100 mg daily
42	100 mg twice daily	Aspirin 75 mg or Clopidogrel 75 mg daily	15	Aspirin or clopidogrel	75 mg daily
40	100 mg twice daily	Placebo Aspirin	40	Placebo and aspirin	Placebo=bd Aspirin=100 mg daily
38	100 mg twice daily	Aspirin 300 mg daily (4 d) then 100 mg daily	38	Aspirin	300 mg daily (4 d) then 100 mg daily
13	200 mg daily	Aspirin 100 mg daily	11	Aspirin	100 mg daily
766	100 mg bd	Aspirin placebo daily	768	Aspirin and placebo	Aspirin=100 mg daily Placebo=bd
11	100 mg daily		9	Aspirin or Clopidogrel	Aspirin=100 mg daily Clopidogrel=50–75 mg daily
251	200 mg daily	Aspirin 300 mg daily	256	Aspirin	Aspirin 300 mg daily
67	100 mg bd	Aspirin 100 mg daily	68	Placebo and aspirin	Aspirin 100 mg daily
232	100 mg bd	Aspirin 75–150 mg daily	225	Clopidogrel and aspirin	Clopidogrel=75 mg daily Aspirin=75–150 mg daily

bd indicates twice daily; CAIST, Cilostazol in Acute Stroke Treatment; CASISP, Cilostazol Versus Aspirin for Secondary Ischemic Stroke Prevention; CATHARSIS, Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis; CE, cardioembolic; Cil, cilostazol; c/o, complaining of; cont, control; CSPS, Cilostazol Stroke Prevention Study; ICA, internal carotid artery; ICH, intracerebral hemorrhage; intracran, intracranial; ipsilat, ipsilateral; IQR, interquartile range; LA, large artery; MCA, middle cerebral artery; NS, not stated; PICASSO, Prevention of Cardiovascular Events in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage; SVD, small vessel disease; TIA, transient ischemic attack; TOSS, Trial of Cilostazol in Symptomatic Intracranial Artery Stenosis; and UK, unknown.

stroke (cilostazol 3477, control 3466; of which, 6 trials, total $n=4964$, included 58% or more lacunar strokes), cilostazol reduced recurrent ischemic stroke (OR=0.64 [95% CI, 0.52–0.79]; $P<0.0001$, without heterogeneity). However, the effect of cilostazol on recurrent ischemic stroke did not differ between the 2 subgroups (<40% or $\geq 40\%$ with lacunar stroke), on formal testing (χ^2 for difference=0.27, $P=0.60$, $I^2=0\%$, $P=0.60$, without heterogeneity).

Time From Stroke to Treatment

Patients allocated treatment within 2 weeks of stroke, and where treatment was generally continued for no more than 4 months, those allocated cilostazol had similar rates of recurrent ischemic stroke (21/972) than those allocated control (19/968), OR=1.10 (95% CI, 0.58–2.05), $P=0.78$ without heterogeneity (Figure VIB in the [Data Supplement](#)). In patients starting treatment beyond 2 weeks after stroke (median), and where treatment was generally continued for 6 months to

5 years, those allocated to cilostazol had fewer recurrent ischemic strokes (189/4155) than those allocated control (286/4130), OR=0.65 (95% CI, 0.54–0.78), $P<0.00001$, without heterogeneity. However, there was no evidence of a between group difference (acute versus late, χ^2 2.47, $P=0.12$, with moderate heterogeneity, $I^2=59.5\%$).

Concomitant Antiplatelet Drugs

Trials which randomized between cilostazol and no cilostazol in the absence or presence of concomitant aspirin or clopidogrel showed similar benefit for cilostazol (no aspirin, OR=0.51 [95% CI, 0.33–0.79]; $P=0.003$; all patients received aspirin or clopidogrel, OR=0.51 [95% CI, 0.35–0.74]; $P=0.0004$) (Figure VIC in the [Data Supplement](#)). However, in trials where cilostazol was compared with aspirin or clopidogrel, including one trial randomizing to cilostazol+aspirin versus clopidogrel+aspirin,¹⁵ there was no definite benefit of cilostazol (OR=0.81 [95% CI, 0.65–1.02]; $P=0.08$). Across the 3 subgroups,

Table 2. Summary of Main Results

Outcome	Trials N	Participants Total N	Cilostazol n/N	Control n/N	OR/SMD (95% CI)	P Value	Subgroup I^2 (%)	χ^2 P Value
All stroke	18	10 225	242/5127	384/5098	0.61 (0.52 to 0.72)	<0.00001	33.5	0.18
Ischemic stroke	18	10 225	210/5127	305/5098	0.68 (0.57 to 0.81)	<0.00001	44.5	0.11
Hemorrhagic stroke	16	9736	30/4885	72/4851	0.43 (0.29 to 0.64)	<0.0001	0	0.55
MACE	10	8948	320/4470	470/4478	0.66 (0.57 to 0.76)	<0.00001	2.5	0.39
Death, all cause	18	10 865	93/5123	144/5742	0.64 (0.49 to 0.83)	0.0009	18.0	0.30
Cognition	2	56	80	72	0.03 (–0.29 to 0.35)	0.84	0.0	0
Headache	14	9582	743/4804	413/4779	2.00 (1.76 to 2.28)	<0.00001	69	0.0001
Dizziness	9	6837	349/3419	292/3418	1.22 (1.04 to 1.44)	0.02	15	0.31
Palpitations	10	9147	281/4566	124/4581	3.14 (2.57 to 3.84)	<0.00001	54	0.02
Tachycardia	5	5396	145/2698	33/2698	3.74 (2.77 to 5.06)	<0.00001	43	0.15
Diarrhea	5	4064	303/2434	126/2403	2.21 (1.78 to 2.74)	<0.00001	41	0.13
Constipation	3	4664	189/2334	268/2330	0.68 (0.56 to 0.82)	0.0001	0	0.72
Nausea	4	3095	76/1548	53/1547	1.47 (1.02 to 2.11)	0.04	0	0.88
Systemic bleeding	12	8387	79/4211	102/4176	0.73 (0.54 to 0.99)	0.04	69	0.001
Sensitivity analysis: effect on ischemic stroke by subgroup								
Ischemic stroke subtype*: <40% lacunar stroke	8	3262	68/1639	101/1623	0.72 (0.49 to 1.07)	0.10	14	0.32
$\geq 40\%$ lacunar stroke	9	6943	142/3477	222/3466	0.64 (0.52 to 0.79)	<0.0001	0	0.54
Test for subgroup difference $\chi^2=0.27$, $P=0.60$, $I^2=0$								
Time to treatment*: <2 wks of stroke (9.6 d)†	8	1940	21/972	19/968	1.1 (0.58 to 2.05)	0.78	0	0.81
≥ 2 wk of stroke (76 d)†	10	8285	189/4155	286/4130	0.65 (0.54 to 0.78)	<0.0001	0	0.52
Test for subgroup difference $\chi^2=2.47$, $P=0.12$, $I^2=59.5$								
Additional antiplatelet drugs: Cil vs no Cil, no antiplatelet	1	1067	30/533	57/534	0.51 (0.33 to 0.79)	0.003	n/a	n/a
Cil+Asp or Clop vs Asp or Clop	8	3044	40/1526	78/1518	0.51 (0.35 to 0.74)	0.0004	0	0.88
Cil vs Asp or Clop	9	6114	140/3068	170/3046	0.81 (0.65 to 1.02)	0.08	0	0.68
Test for subgroup difference $\chi^2=.31$, $P=0.04$, $I^2=68.3$								

Cil indicates cilostazol; MACE, major adverse cardiovascular events; n/a, not applicable; n/N, number of events/total number allocated to that group; OR, odds ratio; and SMD, standardized mean difference.

*Comparison is any cilostazol vs no cilostazol.

†Median time to randomization/treatment.




Figure 2. Effect of cilostazol on ischemic stroke.

CAIST indicates Cilostazol in Acute Stroke Treatment; CSPS, Cilostazol Stroke Prevention Study; and TOSS, Trial of Cilostazol in Symptomatic Intracranial Artery.

there was evidence of between-subgroup differences (χ^2 , 6.31; $P=0.04$), and moderate heterogeneity ($I^2=68.3\%$). Restricting the analysis to trials comparing cilostazol with

one antiplatelet drug in the absence of another antiplatelet drug by excluding the TOSS2 trial showed benefit of cilostazol over the other antiplatelet drug (OR=0.78 [95% CI,




Figure 3. Effect of cilostazol on hemorrhagic stroke.

CASISP indicates Cilostazol Versus Aspirin for Secondary Ischemic Stroke Prevention; CATHARSIS, Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis; and CSPS, Cilostazol Stroke Prevention Study.

0.62–0.99]; $P=0.04$, without heterogeneity) and removed the evidence of between-subgroup difference (χ^2 , 5.19; $P=0.07$), but retained heterogeneity ($I^2=61.4\%$).

Meta-Regression

Meta-regression of time to treatment, duration of treatment, and proportion of lacunar strokes, adjusted for comparator antiplatelet agent, did not identify any significant subgroup effects on outcomes of recurrent ischemic or hemorrhagic stroke.

Sources of Bias

The median trial quality was 23.5/37 (minimum 14, maximum 35), with methods sections attaining the lowest scores on average (Table III and Figure VII in the [Data Supplement](#)).

Funnel plots on all stroke and ischemic stroke showed some skew suggesting reporting bias but not for hemorrhagic stroke did not show any skew (Figure VIII in the [Data Supplement](#)).

DISCUSSION

Cilostazol reduced recurrent stroke, recurrent ischemic stroke, recurrent hemorrhagic stroke, death and major adverse cardiovascular events compared with control, in the presence or absence of aspirin, or when compared directly with aspirin (data were limited for comparison with clopidogrel). Most benefit occurred in trials that randomized patients at 2 or more weeks after stroke and administered cilostazol for at least 6 months or longer, without evidence of increased risk with long-term treatment. There were very few data on the effect of cilostazol on functional outcome, cognitive decline, or radiological markers of SVD. Adverse symptoms such as headache, palpitations, dizziness, and diarrhea were clearly increased with cilostazol although, importantly, systemic bleeding events were reduced.

The review limitations are related to the available data and include variation between trials in antiplatelet drug use, times to randomization after stroke, durations of treatment, not reporting dependency outcomes, and lack of information on stroke subtypes. Included studies varied greatly in sample size and some studies had no events in either group for certain outcomes. Antiplatelet therapy has changed since some studies were completed. Guidelines now advise dual antiplatelets short term after transient ischemic attack or minor ischemic stroke, followed by clopidogrel longer term. Only one study compared cilostazol to clopidogrel and both groups also received aspirin.¹⁵ Only 2 trials recruited patients with cognitive presentations and only one trial in stroke assessed cognition. The median trial quality was moderate (23.5/37). Thus, despite the total available data from trials of cilostazol totaling over 10 000 patients, the

conclusions have limitations. There were also strengths of the review, including prospective protocol registration, assessment of methodological quality, double assessment of papers and data extraction, and careful harmonization of the trials for analysis.

Cilostazol may have more benefit on several outcomes where participants were randomized later after stroke. Although arbitrary, the trials naturally dichotomized into those randomizing within 2 weeks of stroke and those randomizing at >2 weeks after stroke, of which about a third randomized between 2 weeks and 6 months and 2 thirds randomized after 6 months. Trials randomizing >6 months after stroke had long durations of treatment and follow-up. Thus, the apparent benefit of cilostazol in trials randomizing late rather than early may reflect the paucity of acute trials, shorter duration of treatment, higher proportion of lacunar strokes, or that cilostazol is less effective in preventing early recurrent stroke. Similar results have been seen with another phosphodiesterase inhibitor dipyridamole (PDE5 inhibitor) with mild-antiplatelet and proendothelial effects,² which reduced stroke recurrence while increasing headache, mostly in Western populations. The risk of stroke recurrence varies by stroke subtype, atherothromboembolic stroke recurrence risk being the highest immediately after transient ischemic attack/minor stroke, then declining, whereas lacunar stroke has lower risk of early recurrence but the rate remains elevated in the longer term.

Cilostazol's apparent greater benefit late after stroke could reflect several possible mechanisms. Weaker antiplatelet effects³ and hence inferior stroke prevention compared with aspirin or clopidogrel early after transient ischemic attack/stroke (when stronger antiplatelet activity may be more beneficial) is supported by the neutral effect of cilostazol on ischemic stroke recurrence compared with aspirin or clopidogrel (Figure VIC in the [Data Supplement](#)). Increasing benefit of cilostazol late after stroke was also demonstrated in CASISP, which found no difference in recurrent stroke between cilostazol and aspirin within 6 months of stroke, but increasing benefit of cilostazol versus aspirin thereafter.²⁶ The increased benefit of cilostazol later after stroke may reflect that its mechanisms of action are more relevant to lacunar stroke where recurrence occurs late, supported by increased benefit in trials including more patients with lacunar stroke (Figure VIA in the [Data Supplement](#)). Potential benefits for lacunar stroke include endothelial stabilization, improved myelin repair, and better astrocyte-to-neuronal energy supply,^{2,11} all of which may take some time to accrue. The lower cerebral and systemic hemorrhage risks would also confer benefit over other antiplatelet drugs, which typically have higher bleeding risk the longer they are given, a reason for early stopping of the SPS3 Trial (dual versus single antiplatelet drugs) for lacunar stroke²⁹ and seen in the present meta-analysis even in the presence of other antiplatelet drugs.

The PICASSO (Prevention of Cardiovascular events in Ischemic Stroke patients with high risk of cerebral hemorrhage) trial suggests that the benefits of cilostazol may extend to reducing recurrent stroke and systemic bleeding even in patients at high risk of intracerebral hemorrhage.²²

More data are needed to overcome the limitations of the current data, to determine the effect of cilostazol on functional and cognitive outcomes after stroke, and on delaying cognitive decline. If the effects of cilostazol seen in laboratory models translate to people (myelin repair, improved neuronal energy supply, and endothelial stabilization) and help to prevent progression of brain injury, then cilostazol might also prevent physical decline seen in SVD. Future studies should compare cilostazol to modern antiplatelet regimes, stratify patients by stroke or cognitive impairment, provide more data on cognitive, imaging and functional outcomes, and on tolerability and compliance. Several ongoing studies address these issues. LACI-2 (ISRCTN 14911850) is assessing cilostazol long-term after lacunar ischemic stroke in the UK including 1-year cognitive and brain magnetic resonance imaging follow-up (target n=400). The COMCID trial (Asia-Pacific) is assessing cilostazol's effects on cognitive function, incident dementia, and hippocampal volumes (NCT02491268). Other trials are assessing short-term effects of cilostazol on cerebrovascular reactivity (eg, Oxford Hemodynamic Adaptation to Reduce Pulsatility Trial [OxHARP], NCT03855332, target n=76).

Cilostazol shows promise for ischemic stroke prevention, with lower risk of hemorrhagic complications, particularly long term. Its place in stroke therapy may be in chronic secondary prevention rather than the acute phase. However, most data are from Asia Pacific countries where stroke etiologies and other factors may differ from other world regions, hence the need for more data. Despite its encouraging safety profile (lower bleeding risk and death), cilostazol causes several symptoms (headache, palpitations, diarrhea, nausea), which may limit tolerance, requiring more data to guide future routine use. It is licenced in Europe and the Americas for treatment of symptomatic peripheral vascular disease and stroke prevention where other antiplatelet agents have failed or are not tolerated. However, more evidence is needed before it is used more widely in stroke in routine practice.

ARTICLE INFORMATION

Received February 16, 2020; final revision received May 6, 2020; accepted June 6, 2020.

Affiliations

Centre for Clinical Brain Science, University of Edinburgh, United Kingdom (C.M., G.W.B., F.M.C., F.D.). Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (J.P.A., P.M.B.). Department of Neurology, Univer-

sity Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Edgbaston, United Kingdom (J.P.A.).

Acknowledgments

C. McHutchison performed article search and data extraction, meta-analysis, drafting, and review of manuscript. G.W. Blair performed protocol design, article search and data extraction, analysis, drafting, and review of manuscript. Dr Appleton performed review of protocol and manuscript. P.M. Bath performed protocol design, and review of manuscript. Dr Wardlaw performed review conception, protocol design, supervision, article search, data extraction, analysis, drafting, review of manuscript, and approval of the final manuscript for submission.

Sources of Funding

Chest Heart Stroke Scotland (Res 14/A157); European Union Horizon 2020 'SVDs@Target' (No. 666881); Fondation Leducq Transatlantic Network on Perivascular Spaces in SVD (16CVD05); UK Dementia Research Institute (DRI Ltd, UK Medical Research Council, Alzheimer's Society, Alzheimer's Research UK); Alzheimer's Society (AS-PG-14-033); Stroke Association (Princess Margaret Research Development Fellowship, Stroke Association-Garfield Weston Foundation Senior Clinical Lectureship); NHS Research Scotland; National Institute of Health Research; British Heart Foundation (CS/15/5/31475).

Disclosures

Dr Wardlaw, P.M. Bath, G.W. Blair, Dr Appleton, and Dr Doubal worked on the LACI-1 and LACI-2 trials testing cilostazol in lacunar stroke. P.M. Bath led systematic reviews of dipyridamole. The other authors report no conflicts.

REFERENCES

- Hachinski V, Einhäupl K, Ganten D, Alladi S, Brayne C, Stephan BCM, Sweeney MD, Zlokovic B, Iturria-Medina Y, Iadecola C et al. Preventing dementia by preventing stroke: the Berlin manifesto. *Alzheimers Dement*. 2019;15:961–984. doi: 10.1016/j.jalz.2019.06.001
- Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. *Int J Stroke*. 2015;10:469–478. doi: 10.1111/ijs.12466
- Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. *Atheroscler Suppl*. 2005;6:13–19. doi: 10.1016/j.atherosclerossup.2005.09.005
- Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH, Bangalore S, Messeri FH. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. *Am J Cardiol*. 2013;112:1230–1234. doi: 10.1016/j.amjcard.2013.05.067
- Tan L, Margaret B, Zhang JH, Hu R, Yin Y, Cao L, Feng H, Zhang Y. Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis. *J Stroke Cerebrovasc Dis*. 2015;24:930–938. doi: 10.1016/j.jstrokecerebrovasdis.2014.12.002
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535. doi: 10.1136/bmj.b2535
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332. doi: 10.1136/bmj.c332
- Brockhaus AC, Grouven U, Bender R. Performance of the Peto odds ratio compared to the usual odds ratio estimator in the case of rare events. *Biom J*. 2016;58:1428–1444. doi: 10.1002/bimj.201600034
- Lee JY, Lee H, Yoo HB, Choi JS, Jung HY, Yoon EJ, Kim H, Jung YH, Lee HY, Kim YK. Efficacy of cilostazol administration in Alzheimer's disease patients with white matter lesions: a positron-emission tomography study. *Neurotherapeutics*. 2019;16:394–403. doi: 10.1007/s13311-018-00708-x
- Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, Kanetaka H, Iwamoto T. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. *Geriatr Gerontol Int*. 2013;13:90–97. doi: 10.1111/j.1447-0594.2012.00866.x
- Blair GW, Appleton JP, Flaherty K, Doubal F, Sprigg N, Dooley R, Richardson C, Hamilton I, Law ZK, Shi Y, et al. Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: the LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. *EclinicalMedicine*. 2019;11:34–43. doi: 10.1016/j.eclinm.2019.04.001
- Han SW, Lee SS, Kim SH, Lee JH, Kim GS, Kim QJ, Koh IS, Lee JY, Suk SH, Lee SI, et al. Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPSe): a multicenter, randomized,

- double-blind, placebo-controlled trial. *Eur Neurol*. 2013;69:33–40. doi: 10.1159/000338247
13. Uchiyama S, Sakai N, Toi S, Ezura M, Okada Y, Takagi M, Nagai Y, Matsubara Y, Minematsu K, Suzuki N, et al; CATHARSIS Study Group. Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS). *Cerebrovasc Dis Extra*. 2015;5:1–13. doi: 10.1159/000369610
 14. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. *Stroke*. 2005;36:782–786. doi: 10.1161/01.STR.0000157667.06542.b7
 15. Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, Yu KH, Koo JS, Wong KS, Lee SH, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. *Stroke*. 2011;42:2883–2890. doi: 10.1161/STROKEAHA.110.609370
 16. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, et al; CSPS 2 Group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. *Lancet Neurol*. 2010;9:959–968. doi: 10.1016/S1474-4422(10)70198-8
 17. Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, et al; CSPS.com Trial Investigators. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. *Lancet Neurol*. 2019;18:539–548. doi: 10.1016/S1474-4422(19)30148-6
 18. Johkura K, Yoshida TN, Kudo Y, Nakae Y, Momoo T, Kuroiwa Y. Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. *Clin Neurol Neurosurg*. 2012;114:876–880. doi: 10.1016/j.clineuro.2012.01.029
 19. Nakamura T, Tsuruta S, Uchiyama S. Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. *J Neurol Sci*. 2012;313:22–26. doi: 10.1016/j.jns.2011.09.038
 20. Ohnuki Y, Ohnuki Y, Kohara S, Shimizu M, Takizawa S. Dual therapy with aspirin and cilostazol may improve platelet aggregation in noncardioembolic stroke patients: a pilot study. *Intern Med*. 2017;56:1307–1313. doi: 10.2169/internalmedicine.56.7760
 21. Shimizu H, Tominaga T, Ogawa A, Kayama T, Mizoi K, Saito K, Terayama Y, Ogasawara K, Mori E; Tohoku Acute Stroke Progressing Stroke Study Group. Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial. *J Stroke Cerebrovasc Dis*. 2013;22:449–456. doi: 10.1016/j.jstrokecerebrovasdis.2013.02.009
 22. Kim BJ, Lee EJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LKS, Yu S, Hwang YH, Lee JS, et al; PICASSO Investigators. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. *Lancet Neurol*. 2018;17:509–518. doi: 10.1016/S1474-4422(18)30128-5
 23. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, et al. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. *Cerebrovasc Dis*. 2011;32:65–71. doi: 10.1159/000327036
 24. Lee SJ, Lee JS, Choi MH, Lee SE, Shin DH, Hong JM. Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. *BMC Neurology*. 2017;17:169. doi: 10.1186/s12883-017-0950-y
 25. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. *J Stroke Cerebrovasc Dis*. 2000;9:147–157. doi: 10.1053/jscd.2000.7216
 26. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, et al; Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. *Lancet Neurol*. 2008;7:494–499. doi: 10.1016/S1474-4422(08)70094-2
 27. Guo JJ, Xu E, Lin QY, Zeng GL, Xie HF. Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. *Neurosci Bull*. 2009;25:383–390. doi: 10.1007/s12264-009-6192-2
 28. Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. *Eur J Neurol*. 2010;17:434–442. doi: 10.1111/j.1468-1331.2009.02837.x
 29. SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. *N Engl J Med*. 2012;367:817–825. doi: 10.1056/NEJMoa1204133